LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

ADMA Biologics Inc

Closed

SectorHealthcare

20.59 3.31

Overview

Share price change

24h

Current

Min

19.93

Max

20.64

Key metrics

By Trading Economics

Income

-85M

27M

Sales

-2.7M

115M

P/E

Sector Avg

24.357

51.198

EPS

0.136

Profit margin

23.435

Employees

685

EBITDA

-4.7M

35M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+53.81% upside

Dividends

By Dow Jones

Next Earnings

7 sie 2025

Market Stats

By TradingEconomics

Market Cap

1.1B

4.9B

Previous open

17.28

Previous close

20.59

News Sentiment

By Acuity

16%

84%

26 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

ADMA Biologics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 kwi 2025, 14:13 UTC

Major Market Movers

ADMA Biologics Shares Hit 52-Week High After FDA Approval

Peer Comparison

Price change

ADMA Biologics Inc Forecast

Price Target

By TipRanks

53.81% upside

12 Months Forecast

Average 30.67 USD  53.81%

High 35 USD

Low 25 USD

Based on 3 Wall Street analysts offering 12 month price targets forADMA Biologics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

N/A / 23.5406Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

26 / 380 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.